Measles and rubella virus vaccine - Mitsubishi Tanabe

Drug Profile

Measles and rubella virus vaccine - Mitsubishi Tanabe

Alternative Names: Mearubik

Latest Information Update: 09 Nov 2011

Price : $50

At a glance

  • Originator BIKEN
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Measles vaccines; Rubella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Measles; Rubella

Most Recent Events

  • 01 Dec 2005 Launched for Measles in Japan (IM)
  • 01 Dec 2005 Launched for Rubella in Japan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top